Submit Article
Back to Journal

SM Case Reports

A Complete Pathologic Response of Triple Negative Invasive Ductal Carcinoma and Inflammatory Breast Cancer Following Neoadjuvant Chemotherapy

[ ISSN : 2473-0688 ]

Abstract
Details

Received: 06-Mar-2017

Accepted: 14-Mar-2017

Published: 20-Mar-2017

Case Report | Volume 3 - Issue 2 | Article DOI :

Download PDF

Alice A. Higdon¹, Rajiv V. Datta¹, Robert Amajoyi¹, and Eric Seitelman¹*

¹ South Nassau Communities Hospital, One Healthy Way, Oceanside, NY 11572, USA

Corresponding Author:

Alice A Higdon, South Nassau Communities Hospital, One Healthy Way, Oceanside, NY 11572, USA, Tel: 270-705-3361; E-mail: aliceahigdon@ gmail.com

Abstract

Neoadjuvant chemotherapy is a mainstay in therapy for Triple Negative Breast Cancer (TNBC) and is found to decrease the nodal metastasis of the disease prior to surgical excision. Triple negative breast cancer is typically aggressive with rapid growth and poor outcomes, having high recurrence rates as well as short intervals from recurrence to death. Chemotherapy is the only systemic treatment available for TNBC patients. These patients that are treated with neoadjuvant chemotherapy successfully and attain a complete pathological response demonstrate improved survival. Inflammatory Breast Cancer (IBC) is also typically very aggressive, and rare, accounting for only 1-6% of breast cancers diagnosed in the United States. Inflammatory breast cancer is a clinical diagnosis and is typically hormone receptor negative, and HER2 positive [1]. This case presentation is that of a combination of rare, aggressive breast cancers which obtained a complete pathological response to neoadjuvant chemotherapy

Citation

Higdon AA, Datta RV, Amajoyi R and Seitelman E. A Complete Pathologic Response of Triple Negative Invasive Ductal Carcinoma and Inflammatory Breast Cancer Following Neoadjuvant Chemotherapy. SM J Case Rep. 2017; 3(2): 1046.